90 Background: RWED denotes data accumulated via EHR as well as cutting edge technology paired with consumer mobile devices. We are reporting data on 105 pts, users of Belong.life, a worldwide mobile application, who received immunotherapy for their various cancers and were asked to reply to a short, targeted survey on their FT while on treatment. Methods: 105 pts anonymously and voluntarily replied to a survey which included 14 general information questions and those describing FT, its most common encountered causes and their personal financial coping strategies. Results: 79% of the pts were USA based. 21% of the pts were < 50 years of age (yoa), 32% were 51-60 yoa and 47% were > 61 yoa. Pts’s stages were Stage 3 in 23% and 4 in 62% with unknown in 15%. There were 36% males and 64% females. The most common cancer diagnosis was lung in 46% followed by kidney in 17%, malignant melanoma in 14% and colorectal in 10%. The prevalent immunotherapy drugs were nivolumab and pembrolizumab in 36% respectively, and ipilimumab in 14% and durvalumab in 10%. Frequently reported FTs were high medical copayments in 35% of the pts, loss of income in 33% and high drugs and treatments copayments in 21%. 41% of the pts were insured by Medicare and 25% by Medicaid and other HMOs. Only 48% of the pts were aware of possible financial difficulties as a result of their diagnosis and treatment, and 34% received pre-treatment financial advice from their doctors which reduced the reported FT from 48% to 30%. When asked about coping strategies, 39% used personal savings, 28% trimmed their private expenses, and 24% received financial support from their families and friends. Conclusions: 105 users of the Belong.life application reported on their FTs experienced while receiving cancer immunotherapy. FT was most prevalent in the older group ( > 61 yoa) due to high medical and treatment copayments. Nearly half of the pts was not aware of the possible FT and only 38% received advisory information from their doctors. Reduced FT prevalence (from 48% to 30%) was reported by those informed pts. Physicians should become aware of their pts’s possible risks for FTs, therefore appropriate advice should be given prior to immunotherapy initiation.

was present in field 1 or 2 on the claim. Descriptive analyses used per-patient-permonth (PPPM) measures and the Kaplan-Meier method.Results: Among pts treated with ICI monotherapy with irAEs (N¼955; 71 y, 54% male, 69% with treatment before ICI), the top HCRU for irAEs was ambulatory visits (0.23 PPPM), followed by inpatient stays (0.09 PPPM; Table ). Mean irAE-related medical costs were $2,359 PPPM, driven by the cost of inpatient stays. 34% of all pts who experienced an irAE had an irAE-related inpatient stay within 12 mo after ICI initiation.Conclusions: Inpatient stays were the driver for irAE-related costs; approximately onethird of pts with an irAE ultimately required an inpatient stay within a year of initiating ICIs. These study findings help elucidate the economic burden associated with the management of ICI irAEs.

e19331 Background: Real-word data obtained through cutting edge technology paired with consumer mobile devices on 310 worldwide pts, members of Belong.life, an international mobile application, who received immunotherapy for diverse solid tumors, was obtained following a short, targeted survey related to the potential development of FT as a result of the reported diagnosis and IOT. Methods: 310 worldwide pts anonymously and voluntarily replied to a 14 questions survey describing their demographics and FT related points including reported causes, health insurances coverages and personal financial coping strategies. In this abstract we present the data on 205 American pts. Results: All 205 pts were US based. 29 pts (14 %) were <50 years of age (yoa), 68 pts (33%) were 51-60 yoa and 108 (53%) were >61 yoa. Pts’s stages were 3 in 39(19%) and 4 in 141 (69%). There were 72 males and 133 females. The most common cancer diagnosis was lung in 96 pts (47%), malignant melanoma in 37(18%), kidney in 29(14%), colorectal in 14(7%) and bladder in 12(6%). The frequent administered immunotherapy drugs were pembrolizumab in 44%, nivolumab in 39%, ipilimumab in 18 % and durvalumab in 13%. Of the 172/205 pts that replied in full to the FT survey, 82/172 (48%) reported FT during their treatment journey. Of them 24/82 (29.3%) received pretreatment FT information from their medical team while 58/82 pts (70.7%) mentioned that they did not receive FT information. Common reported FTs were high medical copayments in 50 % of the repliers, loss of income in 47% and high drugs and treatment copayments in 38 %. 41 % of the pts were insured by Medicare and 23 % by Medicaid and other HMOs. When asked about coping strategies, 62 % used personal savings, 35% received financial support from family and friends and 32 % trimmed their household expenses. Conclusions: 205 American pts members of the Belong.life application reported on their FTs experiences while receiving cancer immunotherapy. 172/205 replied to the complete survey. FT was most prevalent in the older group (>61 yoa) due to high medical and treatment copayments. Nearly half of the pts were not aware of the possible development of FT before treatment and only 29.3% received pre-treatment advisory information from their doctors. Reduced FT incidence (from 70.7% to 29.3%) was reported by those pts who received financial advice prior to initiation of treatment. Physicians should become aware of their pts’ possible risks for FTs and follow it up with relevant advice prior to immunotherapy initiation.

e18060 Background: RWD denotes data accumulated via electronic health records as well as cutting edge technology paired with consumer mobile devices. Artificial intelligence (AI) incorporates the use of algorithms and machine learning (ML) software to analyze complex medical data, improving the knowledge of cancer journeys. PRO on 256 BC patients (pts) survey repliers, users of Belong.life, a worldwide social media application for cancer pts, are presented. Methods: From 11/2018 to 01/2019, 256 pts replied to a 37 questions’ survey which included information regarding clinical and emotional S/E, FT and CM use. Results: 98 pts (38%) were < 50 years of age, 158 (62%) > 50 years. Most of the pts (163, 64%) were diagnosed within 2017-8. Most pts had Stage 1 (83 pts,32%) and 2 (94 pts,37%) and 71 pts (28%) had Stage 3-4. 154 (61%) had neo-adjuvant anthracyclines-based treatments, followed by a taxane (docetaxel/paclitaxel). 149 of 256 pts (58%) reported clinical S/E: nausea and vomiting in 77 pts (52%), fatigue in 63 pts (42%), hair loss in 42 pts (28%) and body pain and neuropathy in 13 pts each (8.8%). 90 pts (35%) described various emotional symptoms: depression in 32 pts (35.6%), anxiety 13 (14.4%), ‘up and down’ feelings in 20 pts (22 %). FT was experienced by 100/208 pts (48%). FT was most prevalent in ages 35-50 (51/85pts, 60%) than in 51-65 (41/100pts, 41%). Main reported causes in both groups were loss or absence from work (33% and 51%) and treatment copayments (40% and 21%). CM use was reported by 42/256 pts (16.4%). Most common CM were nutritional, multivitamins, supplements and CBD oil use. ML documented a strong relationship between BC recurrence in 55/256 pts (21.5%), FT in 25/55 pts (45.5%) and CM use in 9/25 pts (36%) vs no FT in 3/30 pts (10%). Conclusions: 256 BC users of the Belong application reported on clinical and emotional S/E, FT and CM use. The high incidence of emotional S/E stresses the need for individualized attention. FT was most prevalent in the younger age group (35-50yrs) due to work loss and treatment copayments. A significant relationship was determined by ML techniques on those patients experiencing BC recurrence, FT and CM use.

e24118 Background: Patient-centered healthcare has focused on incorporating the values of patients (Pts) during clinical decision-making. Accordingly, assessments are often executed with patient reported outcome measurements (PROMs). In the context of tumors located in a sexual organ, life quality may be predicated on the perception of the patient’s partner when such a relational dyad exists. Therefore, we created a “partner” reported outcome measurements (pROMs). Accordingly, we sought to query the interconnection of PROMs and pROMs in the setting of early breast cancer (EBC) by using a digital health technology application. Methods: In this ongoing study, 93 EBC Pts and 18 partners, active members of Belong.life, a social engagement platform for cancer Pts and caregivers, replied anonymously and voluntarily to a targeted survey related to sexuality and intimacy parameters in the Pts and their partners. 72% of the partners were 50-69 years of age (yoa), 61% were Caucasian. 70% of the Pts were 50-69 yoa and 72% Caucasian. 72% of the Pts and 78% of the partners had college and university degrees. At diagnosis 78% of the Pts had Stages 1-2, 44% had breast conserving surgery, and most (78%) received chemotherapy. Results: We report the interim results of the first 14 patients-partner dyads. At the time of diagnosis, 86% of partners and 50% of Pts were very or extremely concerned about the patient’s health. Of note, 43% of Pts were not concerned at all or slightly concerned about their own health. With the passage of time, the concern about the patient’s health had decreased to 50% among the partners and 28% among the Pts. Regarding intimacy and sexuality issues prior to the EBC diagnosis, 64% of the Pts didn’t have any complaints but it changed dramatically after diagnosis with 50% mentioning less sex drive and 40% less intimacy. In the partners group 67% didn’t have complaints before the diagnosis but 28% voiced complaints after the diagnosis. Only half of Pts and partners felt they could speak freely about their mutual feelings. Only 23% of Pts and 11% of partners indicated they would agree to seek professional help for issues related to sexuality and intimacy. Ultimately, 71% of Pts and 79% of partners felt happy with each other. Conclusions: Partners were very concerned about the health of Pts; however, the dyad was not always synchronized. Notwithstanding it, the dyad adjusted their concerns during the course of treatment. Body changes had modest effect on the relationship. While dissatisfaction of sexual activity was evident it did not significantly affect the feelings of patients and partners towards each other. The development of pROMs could re-synchronize the dyad thereby creating a more meaningful cancer journey.